World Psoriasis Day 2025
October 29, 2025
What is psoriasis?
Psoriasis is a chronic immune-mediated disease affecting 125 million people worldwide. Although psoriasis commonly manifests as a skin disease, presenting with thick, scaly and sometimes itchy and painful patches on the skin, individuals with psoriasis are also at higher risk of developing serious comorbidities (e.g. psoriatic arthritis, cardiovascular disease, and diabetes) due to underlying systemic inflammation, and mental health disorders (e.g. depression and anxiety) due to the detrimental impact of the disease on quality of life (QoL) and the burden of visible skin lesions.
Since 2014, psoriasis has been recognized by the World Health Organization (WHO) as “a chronic, noncommunicable, painful, disfiguring, and disabling disease for which there is no cure“. In May 2025, the WHO declared skin diseases as a global public health priority, which brings additional consideration to affected patients and gives them hope.
Psoriasis treatment
Although there is currently no cure for psoriatic disease, a wide range of treatments have been developed to help control and manage the signs and symptoms, and lower the risk of associated comorbidities. The treatment strategy depends on the type and severity of disease, with therapeutic options including:
- Topical treatments (steroid and non-steroid treatments)
- Phototherapy
- Conventional systemic treatments
- Biological therapies
World Psoriasis Day 2025
Each year on October 29th, the global community comes together to raise awareness, call for better care, and support people living with psoriatic disease. For 2025, the focus for World Psoriasis Day is Psoriatic Disease and Comorbidities. To learn more about psoriasis and discover how you can help raise awareness of the link between psoriasis and related health conditions, visit the National Psoriasis Foundation (NPF) and International Federation of Psoriasis Associations (IFPA) websites.
Santé Active Edition – Synergy Pharm: How can we help?
In addition to spreading the word to foster awareness and engagement, World Psoriasis Day provides us with an ideal opportunity to highlight the expertise of our medical and scientific communication agency in the field, and remind our clients of the range of medical and scientific writing, editing, and support services we have on offer.
Psoriasis: one of our fields of expertise
Santé Active Edition – Synergy Pharm provides a range of services to assist our clients with all aspects of medical and scientific writing, and psoriasis is a frequent topic covered during our scientific and medical communication activities. As an update to our previous news article dedicated to World Psoriasis Day, below are some examples of how we work with our clients to help them share their research with scientific and medical audiences, as well as with the wider public.
Medical and scientific writing: Disseminating the results of your research
Our experienced medical writers have drafted multiple articles on the topic of psoriasis that have been published in peer-reviewed journals, including two original articles (detailing the results of studies on psoriasis management, one involving the biologic infliximab and the other, as part of a special issue, evaluating the use of a celastrol-containing balm as adjunct care), as well as a literature review focusing on the various pathophysiological mechanisms involved in the disease.
Psoriasis: what’s new at Santé Active Edition – Synergy Pharm?
Our medical writing team assisted in the preparation of an article, published in 2025 in the peer-reviewed journal Dermatologic Therapy, describing the results of an observational survey-based study that examined the decision-making practices of French dermatologists when optimizing the clinical management of individuals with psoriasis.
The study used an innovative case vignette approach to generate a wide range of virtual psoriasis case profiles, representing patients with mild to moderate-to-severe disease, with or without joint involvement or visible skin lesions, various impacts on health-related QoL (HRQoL), and receiving different treatment regimens (topical treatment and/or conventional systemic treatments or biological therapies). After reviewing the virtual case vignettes, the dermatologists responded to the survey by providing suggestions for how they would optimize the current treatment strategy.
Analysis of the responses allowed the authors to gain valuable insights into how dermatologists in private and/or hospital-based settings in France would adjust or switch clinical management strategies to gain better control of psoriatic disease. The study also identified key factors (impact of psoriasis on HRQoL, joint involvement and persistent skin lesions) influencing the decision-making process, thus providing data that could have an impact on future clinical practice guidelines and recommendations.
To find out more, read the full version of the research article, available in open access: Therapeutic Strategies and Decision-Making to Optimize Psoriasis Treatment: A French National Survey Based on Virtual Case Vignettes
Many thanks to the authors for placing their trust in our services.
Language-editing: Article revision by native speakers helps our clients present their research clearly to the widest possible audience
Besides drafting scientific and medical manuscripts, we also have extensive experience in revising and language-editing articles in the field of psoriasis, including English-language original articles, reviews, and letters to the editor, covering a broad range topics: systemic and biological treatments, management of psoriasis in specific populations (i.e., children, adolescents and older adults), and psoriasis subforms (e.g. palmoplantar plaque psoriasis), as well as issues such as therapeutic inertia and the impact of the Covid-19 pandemic on disease management. Links to some of these publications are provided below*.
Translating to ensure the quality and homogeneity of care
The international exchange of knowledge and clinical practice experience is essential for improving patient management for all diseases and contributes to the homogeneity of care and care equality. The dissemination of national guidelines to an international audience is key part of this process and our team (which includes a native English speaker) are proud to have contributed to knowledge transfer in psoriasis by translating into English the French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults.
Writing for the general public: Adapting language to the target audience
Communicating effectively with a wider audience using clear and accessible language is essential for keeping the general public and patients up to date with the latest research and developments in the field. Our team members also have experience in lay medical writing, providing our clients with documents for the wider public to be published in a range of formats (websites, medical brochures and leaflets, patient magazines, general public health guides, etc). Our lay writing expertise includes psoriasis, and we have already assisted clients to write a patient web file and a scientific press release.
What else can we do to help?
Santé Active Edition – Synergy Pharm provides a range of other editorial services to assist our clients with all aspects of medical and scientific publishing, including proofreading (pre- and post-submission), referencing and sourcing, formatting of articles according to journal guidelines, and drafting reviewer responses. We can also help our clients with the preparation of submission documents (conflict of interest declarations, graphical abstracts, cover letters, etc.) and take care of the entire submission process. Find out more about our editorial assistance services: https://www.synpharm.com/en/editorial-assistance-services/
We are happy and proud to assist our clients with their varied projects, and move science forward with our medical writing services, including psoriasis research!
*Some examples of published articles on the topic of psoriasis after revision using our language-editing service:
Drug survival of systemic treatments for severe paediatric psoriasis: An international retrospective study. J Eur Acad Dermatol Venereol. 2025
Impact of excess weight on clinical features of psoriasis and efficacy of biologic therapies in children with severe psoriasis: Analysis of data from the BiPe cohorts. Ann Dermatol Venereol. 2025
Effectiveness of biologic therapies in children with palmoplantar plaque psoriasis: An analysis of real-life data from the BiPe cohorts. Pediatric Dermatology. 2023
Impact of the COVID-19 pandemic on children with psoriasis. Ann Dermatol Venereol. 2021
Therapeutic Inertia in the Management of Moderate-to-Severe Plaque Psoriasis in Adolescents. Acta Derm Venereol. 2021
Perspectives on the pharmacological management of psoriasis in pediatric and adolescent patients. Expert Rev Clin Pharmacol. 2021
Real-World Effectiveness and Safety of Apremilast in Older Patients with Psoriasis. Drugs Aging. 2020